赛诺菲CEO变更与2026年财务展望引关注

Executive Changes - Sanofi announced the appointment of Belén Garijo as the new CEO, effective April 29, 2026, following the decision not to extend the term of current CEO Paul Hudson [2] Financial Performance - The company expects sales to grow at a high single-digit percentage in 2026, with earnings per share growth slightly exceeding sales growth, and plans to execute a €1 billion stock buyback to support shareholder returns [3] Company Fundamentals - Sanofi faces risks of declining vaccine sales due to U.S. policy impacts and is overly reliant on its flagship product Dupixent, which has a patent expiration in 2031, necessitating accelerated new drug development to address patent cliff pressures [4] - Recent disappointing trial results over the past 12 months have led investors to focus on potential pipeline breakthroughs in 2026 [4] Business Developments - Two cardiovascular drugs, Afikaytai and Praluent, received approval in China from late 2025 to early 2026, demonstrating the company's ability to accelerate the launch of innovative drugs through business expansion strategies, which may contribute to regional growth [5]